{"id":34436,"date":"2026-01-06T18:19:13","date_gmt":"2026-01-06T17:19:13","guid":{"rendered":"https:\/\/tirzepatyd.eu\/?post_type=product&p=34436"},"modified":"2026-04-18T11:50:26","modified_gmt":"2026-04-18T09:50:26","slug":"retatrutide-20mg","status":"publish","type":"product","link":"https:\/\/tirzepatyd.eu\/cs\/produkt\/retatrutide-20mg\/","title":{"rendered":"Triple G 20mg mg lahvi\u010dka GLP3"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

GLP3 retatrutid 20mg - charakteristiky\u00a0<\/h2>

Retatrutid 20 mg, ozna\u010dovan\u00fd tak\u00e9 jako GLP3 reta, je syntetick\u00fd aminokyselinov\u00fd v\u00fdzkumn\u00fd peptid vyvinut\u00fd jako trojit\u00fd agonista receptor\u016f GLP-1, GIP a glukagonu. Tato slou\u010denina pat\u0159\u00ed k nov\u00e9 generaci multireceptorov\u00fdch molekul, kter\u00e9 jsou analyzov\u00e1ny ve studi\u00edch metabolick\u00e9 regulace, homeost\u00e1zy gluk\u00f3zy a energetick\u00e9 rovnov\u00e1hy.<\/p>

Charakteristick\u00fdm rysem GLP3 reta (retatrutidu) je jeho sou\u010dasn\u00e1 aktivita v\u016f\u010di t\u0159em kl\u00ed\u010dov\u00fdm sign\u00e1ln\u00edm os\u00e1m. Aktivace receptoru GLP-1 je analyzov\u00e1na v kontextu regulace chuti k j\u00eddlu, zpo\u017ed\u011bn\u00e9ho vyprazd\u0148ov\u00e1n\u00ed \u017ealudku a vlivu na mechanismy sytosti. Receptor GIP z\u016fst\u00e1v\u00e1 zapojen do modulace sekrece inzulinu a metabolick\u00e9 odpov\u011bdi v z\u00e1vislosti na gluk\u00f3ze, zat\u00edmco u glukagonov\u00e9 slo\u017eky se zkoum\u00e1 jej\u00ed vliv na energetick\u00fd v\u00fddej a metabolismus substr\u00e1t\u016f. Pr\u00e1v\u011b tento komplexn\u00ed receptorov\u00fd profil \u010din\u00ed z p\u0159\u00edpravku Retatrutid 20 mg d\u016fle\u017eit\u00fd studijn\u00ed materi\u00e1l p\u0159i anal\u00fdz\u00e1ch modern\u00ed metabolick\u00e9 farmakologie.<\/p>

Kde koupit Retatrutide 20mg online dostupnost<\/h2>

GLP3 reta neboli retatrutid nen\u00ed v sou\u010dasn\u00e9 dob\u011b standardn\u011b dostupn\u00fd v l\u00e9k\u00e1rn\u00e1ch.<\/strong>. Tato l\u00e1tka je v pokro\u010dil\u00e9 f\u00e1zi klinick\u00fdch studi\u00ed a dosud nebyla obecn\u011b registrov\u00e1na jako l\u00e9\u010div\u00fd p\u0159\u00edpravek pro b\u011b\u017en\u00e9 pou\u017eit\u00ed.<\/p>

Jedin\u00fdmi leg\u00e1ln\u00edmi a l\u00e9ka\u0159sky kontrolovan\u00fdmi formami p\u0159\u00edstupu k retatrutidu jsou programy klinick\u00fdch zkou\u0161ek<\/strong>. V\u00fdrobky ozna\u010dovan\u00e9 na internetu jako \u201ev\u00fdzkumn\u00fd peptid\u201d nebo \u201ev\u00fdzkumn\u00fd peptid\u201d nejsou l\u00e9ky schv\u00e1len\u00fdmi pro hum\u00e1nn\u00ed pou\u017eit\u00ed a jejich kvalita a slo\u017een\u00ed nepodl\u00e9haj\u00ed stejn\u00fdm standard\u016fm kontroly jako farmaceutick\u00e9 v\u00fdrobky.<\/p>

Z hlediska bezpe\u010dnosti GLP3 reta<\/strong> by m\u011bly b\u00fdt pova\u017eov\u00e1ny pouze za zkou\u0161en\u00e1 l\u00e1tka<\/strong>, a ne jako spot\u0159ebitelsk\u00fd produkt.<\/p>

V\u00fdzkum metabolismu<\/h2>

Klinick\u00e9 studie prok\u00e1zaly, \u017ee retatrutid 20 mg m\u00e1 velmi siln\u00fd \u00fa\u010dinek na sn\u00ed\u017een\u00ed hmotnosti u ob\u00e9zn\u00edch dosp\u011bl\u00fdch, co\u017e bylo potvrzeno v randomizovan\u00fdch placebem kontrolovan\u00fdch studi\u00edch prov\u00e1d\u011bn\u00fdch po dobu a\u017e 48 t\u00fddn\u016f.<\/p>

V t\u00e9to studii bylo hodnoceno n\u011bkolik d\u00e1vek retatrutidu, kter\u00e9 byly aplikov\u00e1ny v postupn\u00e9m stup\u0148ov\u00e1n\u00ed. Byl pozorov\u00e1n jasn\u00fd vztah mezi d\u00e1vkou a \u00fa\u010dinkem, kdy vy\u0161\u0161\u00ed d\u00e1vky byly spojeny s v\u011bt\u0161\u00edm \u00fabytkem hmotnosti. Ve skupin\u00e1ch, kter\u00e9 dost\u00e1valy nejvy\u0161\u0161\u00ed d\u00e1vky, dos\u00e1hl pr\u016fm\u011brn\u00fd pokles hmotnosti p\u0159ibli\u017en\u011b 24-26% p\u016fvodn\u00ed hmotnosti, co\u017e je jeden z nejvy\u0161\u0161\u00edch v\u00fdsledk\u016f zaznamenan\u00fdch ve studi\u00edch farmakologick\u00e9 l\u00e9\u010dby obezity.<\/p>

Pomocn\u00e9 anal\u00fdzy uk\u00e1zaly, \u017ee \u00fabytek hmotnosti byl postupn\u00fd a trval\u00fd v pr\u016fb\u011bhu l\u00e9\u010dby, bez n\u00e1hl\u00e9ho n\u00e1r\u016fstu v posledn\u00edch t\u00fddnech studie. Sn\u00ed\u017een\u00ed hmotnosti se t\u00fdkalo p\u0159edev\u0161\u00edm tukov\u00e9 tk\u00e1n\u011b, co\u017e sv\u011bd\u010d\u00ed o p\u0159\u00edzniv\u00e9m \u00fa\u010dinku retatrutidu na t\u011blesn\u00e9 slo\u017een\u00ed, a nikoli pouze o kr\u00e1tkodob\u00e9m \u00fabytku hmotnosti v d\u016fsledku dehydratace nebo \u00fabytku libov\u00e9 t\u011blesn\u00e9 hmoty.<\/p>

N\u00e1vrhy studi\u00ed GLP3 Retatrutid 20 mg a pozorov\u00e1n\u00ed studi\u00ed<\/h2>

GLP3 rheta (retatrutid) nem\u00e1 schv\u00e1len\u00e9 d\u00e1vkovac\u00ed sch\u00e9ma pro pacienty, proto\u017ee se st\u00e1le jedn\u00e1 o zkou\u0161enou l\u00e1tku a ve\u0161ker\u00e9 informace o d\u00e1vkov\u00e1n\u00ed poch\u00e1zej\u00ed pouze z protokol\u016f klinick\u00fdch studi\u00ed f\u00e1ze II a III.<\/p>

Krom\u011b zm\u011bn t\u011blesn\u00e9 hmotnosti byl reatrutid 20 mg (GLP3 reta) ve studi\u00edch analyzov\u00e1n tak\u00e9 na dal\u0161\u00ed metabolick\u00e9 parametry. U osob s diabetem 2. typu byla pozorov\u00e1na lep\u0161\u00ed kontrola glyk\u00e9mie, kter\u00e1 souvisela s \u00fa\u010dinkem l\u00e1tky na gluk\u00f3zo-dependentn\u00ed inzulinotropn\u00ed odpov\u011b\u010f a vybran\u00e9 ukazatele metabolick\u00e9 citlivosti.<\/p>

Dostupn\u00e9 anal\u00fdzy t\u011blesn\u00e9ho slo\u017een\u00ed uk\u00e1zaly, \u017ee pozorovan\u00e9 zm\u011bny se t\u00fdkaly p\u0159edev\u0161\u00edm tukov\u00e9 tk\u00e1n\u011b, co\u017e je d\u016fle\u017eit\u00e9 pro posouzen\u00ed kvality metabolick\u00e9 reakce. V publikac\u00edch byly pops\u00e1ny tak\u00e9 p\u0159\u00edzniv\u00e9 zm\u011bny vybran\u00fdch kardiometabolick\u00fdch parametr\u016f, v\u010detn\u011b ukazatel\u016f souvisej\u00edc\u00edch s metabolismem lipid\u016f a energetick\u00fdm metabolismem.<\/p>

Pod\u00edvejte se tak\u00e9 na GLP-1 (Orforglipron) kapsle 5mg\/60caps<\/a><\/p>

\"GLP3<\/a><\/p>

V\u011bdeck\u00e9 zdroje:<\/strong><\/p>

1. PubMed - klinick\u00e9 hodnocen\u00ed retatrutidu u ob\u00e9zn\u00edch osob (48 t\u00fddn\u016f)<\/strong>
https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/<\/a>
Potvrzuje mechanismus \u00fa\u010dinku jako triagonista GLP-1\/GIP\/glukagonu a vysokou redukci hmotnosti.<\/p>

2. The New England Journal of Medicine - \u00fapln\u00e9 zve\u0159ejn\u011bn\u00ed v\u00fdsledk\u016f studie<\/strong>
https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972<\/a>
Popisuje \u00fa\u010dinnost (a\u017e ~24% \u00fabytku hmotnosti), bezpe\u010dnostn\u00ed profil a klinick\u00fd v\u00fdznam.<\/p>

3. PubMed - Studie f\u00e1ze II u pacient\u016f s diabetem 2. typu<\/strong>
https:\/\/pubmed.ncbi.nlm.nih.gov\/37385280\/<\/a>
Potvrzuje zlep\u0161en\u00ed kontroly glyk\u00e9mie a sou\u010dasn\u00e9 sn\u00ed\u017een\u00ed hmotnosti.<\/p>

4. PubMed - anal\u00fdza d\u00e1vky a sn\u00e1\u0161enlivosti retatrutidu<\/strong>
https:\/\/pubmed.ncbi.nlm.nih.gov\/38858523\/<\/a>
Popisuje sch\u00e9mata zvy\u0161ov\u00e1n\u00ed d\u00e1vky a vztah mezi d\u00e1vkou a \u00fa\u010dinkem a d\u00e1vkou a \u00fa\u010dinkem.<\/p>

5. NEJM - redak\u010dn\u00ed koment\u00e1\u0159 o triagonistech (\u201eTriple G\u201d)<\/strong>
https:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJMe2307282<\/a>
Vysv\u011btluje v\u00fdznam retatrutidu jako nov\u00e9 generace l\u00e9\u010dby obezity.<\/p>

V\u00fdrobek je ur\u010den pro v\u011bdeck\u00fd v\u00fdzkum a laboratorn\u00ed anal\u00fdzy. V\u0161echny \u010dl\u00e1nky a informace na t\u011bchto webov\u00fdch str\u00e1nk\u00e1ch slou\u017e\u00ed pouze k informa\u010dn\u00edm a vzd\u011bl\u00e1vac\u00edm \u00fa\u010del\u016fm.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Triple G 20 mg<\/strong> je syntetick\u00fd v\u00fdzkumn\u00fd peptid pat\u0159\u00edc\u00ed do skupiny receptorov\u00fdch triagonist\u016f. Je navr\u017een tak, aby sou\u010dasn\u011b aktivoval receptory GLP-1, GIP a glukagonu, kter\u00e9 hraj\u00ed kl\u00ed\u010dovou roli v regulaci metabolismu a energetick\u00e9ho metabolismu.<\/p>","protected":false},"featured_media":34437,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[124,109,15],"product_tag":[136],"class_list":{"0":"post-34436","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-produkty-w-fiolce","7":"product_cat-triple-g","8":"product_cat-laboratory-research","9":"product_tag-fiolka","11":"first","12":"instock","13":"sale","14":"shipping-taxable","15":"purchasable","16":"product-type-simple"},"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/tirzepatyd.eu\/cs\/wp-json\/wp\/v2\/product\/34436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tirzepatyd.eu\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/tirzepatyd.eu\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/cs\/wp-json\/wp\/v2\/comments?post=34436"}],"version-history":[{"count":51,"href":"https:\/\/tirzepatyd.eu\/cs\/wp-json\/wp\/v2\/product\/34436\/revisions"}],"predecessor-version":[{"id":35470,"href":"https:\/\/tirzepatyd.eu\/cs\/wp-json\/wp\/v2\/product\/34436\/revisions\/35470"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/cs\/wp-json\/wp\/v2\/media\/34437"}],"wp:attachment":[{"href":"https:\/\/tirzepatyd.eu\/cs\/wp-json\/wp\/v2\/media?parent=34436"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/cs\/wp-json\/wp\/v2\/product_brand?post=34436"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/cs\/wp-json\/wp\/v2\/product_cat?post=34436"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/cs\/wp-json\/wp\/v2\/product_tag?post=34436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}